前列负阴方治疗激素依赖性前列腺癌的临床对照研究  

A clinical controlled study on Qianliefuyinfang combined with mordon chemical drugs for the treatment of Androgen dependent prostatic carcinoma(ADPC)

作　　者：龚华[1] 徐成林 郁超[1,2,3] 顾勇刚 陈磊 应荐[5] 赵友康 曹宏文 何晓锋 JittikornPimolsettapun[1] 张志航 Gong Hual;Xu Chenglin;Yu Chao;Gu Yonggang;Chen Lei;Yin Jian;Zhao Youkang;Cao Hongwen;He Xiaofeng;Jittikom Pimolsettapun;Zhang Zhihang(Department of Urology & Andrology, The LongHua Hospital, Shanghai, 200032)

机构地区：[1]上海中医药大学附属龙华医院泌尿外科,上海200032 [2]上海市名中医周智恒泌尿男科工作室,上海200032 [3]上海市中西医结合前列腺癌特色专科,上海200032 [4]上海市浦东医院,上海201209 [5]上海市气功研究所,上海200032

出　　处：《中国男科学杂志》2019年第3期37-41,共5页Chinese Journal of Andrology

基　　金：上海市海派中医流派传承人才培养项目(LPRC2017015);上海市科委医学引导项目(18401904400);上海市卫计委中医特色诊疗技术建设项目(TSJS2016023);全国中医药高等教育学会临床教育研究会临床教学科研课题(2017062)

摘　　要：目的观察中药前列负阴方干预治疗激素依赖性前列腺癌的临床效果。方法将146例激素依赖性前列腺癌患者随机分为对照组与治疗组,每组73例。对照组予去势加内分泌治疗,治疗组在对照组治疗措施基础上,加服前列负阴方治疗。两组疗程均为6个月,随访至终点时间或研究截止,观察前列腺癌患者生活质量、比较前列腺特异性抗原(PSA)的倍增情况、去势抵抗发生率及远处转移和终点事件发生率。结果(1)治疗组患者生活质量、临床症状改善明显高于对照组,两组比较差异有统计学意义。(2)两组PSA倍增情况比较,差异有统计学意义,治疗组明显低于对照组(P<0.05)o (3)治疗组、对照组去势抵抗前列腺癌发生率分别为19.44%、67.14%,治疗组明显低于对照组(P<0.05)o (4)两组骨等远处转移发生率及终点事件发生率比较,治疗组均明显低于对照组(P<0.05)c结论前列负阴方干预常规现代药物去势内分泌治疗激素依赖性前列腺癌后可有效提高患者生活质量,改善临床症状,能减少“抑雄”的副作用,一定程度增加现代药物治疗激素依赖性前列腺癌的疗效,延缓前列腺癌进入激素抵抗阶段的发生,减少骨等远处转移,延长生存时间。Objective To observe clinical efficacy of Qianliefuyinfang combined with mordon chemical drugs in the treatment of androgen dependent prostatic carcinoma. Methods A total of 146 patients with ADPC were randomly divided into the treatment group (treated by TCM herbs of Qianliefuyinfang combined with mordon chemical drugs) and the control group(treated only by mordon chemical drugs).The assessment was made after 3 treatment cycle times. Results The patients in treatment group had significant improvement in the quality of life and the clinical symptoms compared with the patients in the control group. There were statistically significant differences in the doubling of PSA between these two groups(P<0.05). The incidence of C R PC in the treatment group and control group were 19.44% and 67.14%, respectively, and the incidence of CRPC in the treatment group was significantly lower than that in the control group (P<0.05);Bone metastases and terminal events between two groups in treatment group were significantly lower than those in the control group(P<0.05).Conclusion Qianliefuyinfang combined with mordon chemical drugs can significantly improve the quality of life and the clinical symptoms of the patients with ADPC by increasing the efficacy of modem drugs in the treatment of ADPC, and inhibiting the CRPC to a certain extent, as well as decreasing bone metastasis and prolonging the survival time.

关 键 词：雄激素依赖性前列腺肿瘤 前列负阴方 中医药 

分 类 号：R737.25[医药卫生—肿瘤]